Chairman: Roberto Solari

Advent Contact: Shahzad Malik

CRAC channel-based drug discovery

Calcico is an early stage company developing small molecule inhibitors of the CRAC channel. These have the potential to address a range of indications in the areas of inflammation, allergy and autoimmunity.

Advent founded Calcico in 2012

Back